SUMMARY An experiment is described which tests for visible and invisible mutants in mice treated with four different doses each of the contraceptives Gynanovlar and Lyndiol.
Combinations of progestins and oestrogens are used widely to prevent conception. However, in spite of numerous biological and clinical investigations (Pincus and Baily, 1964; Yen and Vela, 1968; Overbeek, 1969; Craft et al., 1970; Song et al., 1970) , the mechanism of action of these substances is not completely understood.
Recent reports have shown that contraceptive drugs of steroid nature induce structural chromosomal aberration both in vivo and in vitro, and that these differ according to the type and aspect of the organism studied. For women, see Carr (1967) , Goh (1967) , McQuarrie et al. (1970) , Badr et al. (1973) . For dogs, see Williams et al. (1968) ; rats, Badr and Badr (1969) ; and onion root tips, Kabarity and Khodari (1967) . For women, however, see also the null findings of Stenchever et al. (1969) and Timson (1969) .
There have been no reports on the mutagenic effect of hormones at the level of gene (point) mutation in any mammal, except those concerning mice (Wolff, 1934; Wolff and Wolff, 1936; Jorg 1940) , which, however, were not consistent.
The present report concerns an experiment on mice, testing two commonly used contraceptive pills for induction of mutation to both lethal and visible mutants, dominants and recessives. The method is based on a standard one (Falconer, 1949) (Staats, 1972 The results fell into three sections.
Litter size and sex ratio, at birth and at weaning, were examined for the two treatments and the control, for the three generations of the main breeding programme (Table 1) . These data allow assessment of the incidence of invisible (lethal) mutants induced therein.
The incidence of visible abnormalities was examined for the various parts of this programme, together with the results of breeding tests for any genetic basis of the abnormalities. These data allow assessment of the incidence of visible mutants induced therein.
Finally, litter size at birth and weaning were examined for the first three litters in generations 23 to 25 of sibmating of the CBA line, together with the incidence of abnormalities over all litters bred in these generations. These are the ultimate control data for assessing the validity of interpretations made from the main breeding programme.
Average litter sizes, with standard errors, were calculated and comparisons between averages were made by the use of Student's t test, except when the size of samples differed appreciably, when the modified t test (Fisher and Yates, 1960) was used. Comparisons between sex ratios were made by the use of the 2 x 2 contingency x2 test (with Yates correction where the total was less than 500).
Similarly, comparisons between postnatal mortalities were made by the use of the contingency x2 test, testing the homogeneity of observed numbers born and died, for a particular group, with the observed numbers born and died for the control.
An assessment of the incidence of invisible (lethal) mutants requires a count to be made of the numbers of antenatal and postnatal deaths in treated groups in excess of those occurring in the control group. This count has to be related to the actual number of treated gametes tested in the case of dominants, or to the 'equivalent' number in the case of recessives. The actual number is the number of Fl progeny raised. The equivalent number is derived from the number of progeny raised in backcross and intercross matings in testing each Fl gamete (Falconer, 1949) . The relevant actual and equivalent numbers are given in Table 2 .
Results

LITTER SIZES AND SEX RATIOS: MAIN BREEDING PROGRAMME
The progenies of the base-line, intercross, outcross, and backcross matings were examined separately. For none of them were there consistently significant differences between any of the four dose groups and the control, for Gynanovlar or Lyndiol, in any of the following: birth litter size, weaning litter size, and sex ratio at birth and at weaning. There was an isolated significant difference (in greater postnatal mortality of Gynanovlar group III over that of the control), but this is offset by two other significant results which favour the (unlikely) beneficial effect of the treatments; these three cases fall within the number of incidently significant values which may be expected when a great number of tests is done.
INCIDENCE OF VISIBLE ABNORMALITIES: MAIN BREEDING PROGRAMME
There were 50 visible abnormalities in the various treated groups and the control groups. But, despite extensive breeding to test heredity, the only abnormality to reappear in relations and descendants of the test programme was 'stumpy' stm (Ferguson et al., 1978) . This mutant appeared among the control matings. Thus, there were no visible mutants in the whole of the main breeding programme. The abnormalities occurred at random through the programme; the Gynanovlar rate was 0 0031 I 0 0009, the Lyndiol rate 0-0026 i 0 0011, and the control rate 0 0028 i 0 0018. (1942) , and is specifically (for the 5% level of probability): Gynanovlar 3 -9 %, Lyndiol 4 15 %, control 20 53 %.
The lower 5 % level for the control is 0 11 %; this, and the estimate of 4-13%, suggests, in agreement with Lyon et al. (1964) , that the spontaneous rate may be higher than that predicted on the basis of specific locus experiments plus the estimated number of mutable loci at 5000 to 10 000.
Thus, there is no case for a gross mutagenic effect of Lyndiol or Gynanovlar.
The high rate of skeletal abnormalities throughout this work raises a query about the overall propensity of the CBA line to express skeletal defects. Unlike the defects in the notorious inbred lines C57BL and BALB/C (Bailey, 1959) , they are mainly of the appendicular skeleton, whereas published information for the parent CBA strain (see pp. 239, 253, and 255 of Gruneberg, 1963) 
